J A Kemp
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich.
The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 50 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.
Karma Oncology is an oncology specialized clinical research organisation. With a team of very experienced oncology project managers, CRAs and CTAs we offer all clinical trial services from preparation of clinical development plans including protocol design, project/study management, monitoring, data review, preparation of the clinical study report and manuscript. Services are customised to individual sponsors and as such we will perform any single aspect of a trial as efficiently and with the same enthusiasm and dedication as we will for the complete trial.
Masters Speciality Pharma
Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.
Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.
We're delighted to introduce our first episode in our video series, OFX Currency Corner. Our resident experts will provide insights on relevant events and trends that impact major currency markets. And what this could mean for you.
In episode one, we look back on the events of 2017 and resultant currency movements. We also take a view on upcoming factors you need to watch out for this month, to help you make the right transfer decisions for your business.
Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.